Page last updated: 2024-09-03

lestaurtinib and gilteritinib

lestaurtinib has been researched along with gilteritinib in 4 studies

Compound Research Comparison

Studies
(lestaurtinib)
Trials
(lestaurtinib)
Recent Studies (post-2010)
(lestaurtinib)
Studies
(gilteritinib)
Trials
(gilteritinib)
Recent Studies (post-2010) (gilteritinib)
124126313512132

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)gilteritinib (IC50)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 26.76
Cannabinoid receptor 1Rattus norvegicus (Norway rat)0.0007
Leukocyte tyrosine kinase receptorHomo sapiens (human)0.0003
Tyrosine-protein kinase receptor UFOHomo sapiens (human)0.0035
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0003
Transcription factor ETV6Homo sapiens (human)0.0085
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.0036
ALK tyrosine kinase receptorHomo sapiens (human)0.0024

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1
Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK1
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM1

Reviews

2 review(s) available for lestaurtinib and gilteritinib

ArticleYear
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Leukemia, 2020, Volume: 34, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome

2020
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine

2020

Other Studies

2 other study(ies) available for lestaurtinib and gilteritinib

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022